How to translate and implement the current science of gene therapy into haemophilia care?

Gene-based therapy opens an entirely new paradigm in managing people with haemophilia (PWH), offering them the possibility of a functional cure by enabling continuous expression of factor VIII (FVIII) or factor IX (FIX) after transfer of a functional gene designed to replace the PWH’s own defective gene. In recent years, significant advances in gene therapy have been made, resulting in clotting factor activity attaining near-normal levels, as reflected by ‘zero bleeding rates’ in previously severely inflicted patients following a single administration of adeno-associated viral (AAV) vectors. While this new approach represents a major advancement, there are still several issues that must be resolved before applying this technology in clinical practice. First, awareness, communication, and education about the therapeutic potential and modalities of gene therapy must be further strengthened. To this end, objective, unbiased, transparent, and regularly updated information must be shared, in an appropriate way and understandable language with the support of patients’ organizations. Second, healthcare providers should adopt a patient-centred approach, as the ‘one size fits all’ approach is inappropriate when considering gene therapy. Instead, a holistic patient view taking into account their physical and mental dimensions, along with unexpressed expectations and preferences, is mandatory. Third, the consent procedure must be improved, ensuring that patients’ interests are maximally protected. Finally, gene therapy is likely to be first delivered in a few centres, with the highest expertise and experience in this domain. Thus, patients should be managed based on a hub-and-spoke model, taking into account that the key to gene therapy’s success lies in an optimal communication and collaboration both within and between haemophilia centres sharing their experiences in the frame of international registries. This review describes recent progress and explains outstanding hurdles that must be tackled to ease the implementation of this paradigm-changing new therapy.

[1]  E. Neufeld,et al.  Gene Therapy and Hemophilia: Where Do We Go from Here? , 2022, Journal of blood medicine.

[2]  L. George,et al.  Adeno-associated Virus Gene Therapy for Hemophilia. , 2022, Annual review of medicine.

[3]  C. Goodman,et al.  The Hemophilia Gene Therapy Patient Journey: Questions and Answers for Shared Decision-Making , 2022, Patient preference and adherence.

[4]  C. Hermans Haemophilia gene therapy: experiences and lessons from treated patients , 2022, Orphanet Journal of Rare Diseases.

[5]  M. Ozelo,et al.  Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A. , 2022, The New England journal of medicine.

[6]  C. Thornburg Prepare the Way for Hemophilia A Gene Therapy. , 2022, New England Journal of Medicine.

[7]  V. Jiménez‐Yuste,et al.  Gene therapy of hemophilia: Hub centres should be haemophilia centres: A joint publication of EAHAD and EHC , 2022, Haemophilia : the official journal of the World Federation of Hemophilia.

[8]  D. Kleinermans,et al.  Is the world ready for gene therapy? , 2022, Haemophilia : the official journal of the World Federation of Hemophilia.

[9]  H. Eichler,et al.  Preparing for tomorrow: Defining a future agenda , 2022, Haemophilia : the official journal of the World Federation of Hemophilia.

[10]  L. Garrison,et al.  Hemophilia Gene Therapy Value Assessment: Methodological Challenges and Recommendations. , 2021, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[11]  S. Simoens,et al.  Patient preferences for gene therapy in haemophilia: Results from the PAVING threshold technique survey , 2021, Haemophilia : the official journal of the World Federation of Hemophilia.

[12]  C. Königs,et al.  Hemophilia treatment in 2021: Choosing the"optimal" treatment using an integrative, patient-oriented approach to shared decision-making between patients and clinicians. , 2021, Blood reviews.

[13]  P. Batty,et al.  Gene therapy for hemophilia: Current status and laboratory consequences , 2021, International journal of laboratory hematology.

[14]  C. Hermans,et al.  Living with a “hemophilia‐free mind” – The new ambition of hemophilia care? , 2021, Research and practice in thrombosis and haemostasis.

[15]  C. Königs,et al.  The Role of Physiotherapy in the New Treatment Landscape for Haemophilia , 2021, Journal of clinical medicine.

[16]  L. Valentino,et al.  Emerging Immunogenicity and Genotoxicity Considerations of Adeno-Associated Virus Vector Gene Therapy for Hemophilia , 2021, Journal of clinical medicine.

[17]  C. Négrier,et al.  Optimizing language for effective communication of gene therapy concepts with hemophilia patients: a qualitative study , 2021, Orphanet Journal of Rare Diseases.

[18]  C. Hermans,et al.  Evolution of haemophilia integrated care in the era of gene therapy: Treatment centre’s readiness in United States and EU , 2021, Haemophilia : the official journal of the World Federation of Hemophilia.

[19]  C. Hermans,et al.  Patient selection for hemophilia gene therapy: Real‐life data from a single center , 2021, Research and practice in thrombosis and haemostasis.

[20]  K. Cornetta,et al.  AAV Joins the Rank of Genotoxic Vectors. , 2021, Molecular therapy : the journal of the American Society of Gene Therapy.

[21]  Laurence Woollard,et al.  Improving patient informed consent for haemophilia gene therapy: the case for change , 2021, Therapeutic advances in rare disease.

[22]  J. Oldenburg,et al.  Long-term outcomes with emicizumab prophylaxis for hemophilia A with/without FVIII inhibitors from the HAVEN 1-4 studies. , 2020, Blood.

[23]  S. Simoens,et al.  PBI55 Patient Preferences for GENE Therapy in Hemophilia: Results from the Paving Threshold Technique Survey , 2020 .

[24]  Richard Gorman,et al.  Addressing patient education priorities in the era of gene therapy for haemophilia: Towards evidence‐informed shared decision‐making , 2020, Haemophilia : the official journal of the World Federation of Hemophilia.

[25]  M. Holland,et al.  Parental perspectives on gene therapy for children with haemophilia: The Exigency study , 2020, Haemophilia : the official journal of the World Federation of Hemophilia.

[26]  J. Astermark,et al.  First Data from the Phase 3 HOPE-B Gene Therapy Trial: Efficacy and Safety of Etranacogene Dezaparvovec (AAV5-Padua hFIX variant; AMT-061) in Adults with Severe or Moderate-Severe Hemophilia B Treated Irrespective of Pre-Existing Anti-Capsid Neutralizing Antibodies , 2020 .

[27]  L. Valentino,et al.  Discussing investigational AAV gene therapy with hemophilia patients: A guide. , 2020, Blood reviews.

[28]  S. Simoens,et al.  Patient perspectives regarding gene therapy in haemophilia: Interviews from the PAVING study , 2020, Haemophilia : the official journal of the World Federation of Hemophilia.

[29]  M. Langeveld,et al.  Registries for orphan drugs: generating evidence or marketing tools? , 2020, Orphanet Journal of Rare Diseases.

[30]  M. Makris,et al.  Evolution of Haemophilia Care in Europe: 10 years of the principles of care , 2020, Orphanet Journal of Rare Diseases.

[31]  A. Srivastava,et al.  Hemophilia gene therapy knowledge and perceptions: Results of an international survey , 2020, Research and practice in thrombosis and haemostasis.

[32]  P. Mannucci Hemophilia therapy: the future has begun , 2020, Haematologica.

[33]  F. Mingozzi,et al.  AAV Vector Immunogenicity in Humans: A Long Journey to Successful Gene Transfer , 2020, Molecular therapy : the journal of the American Society of Gene Therapy.

[34]  M. Recht,et al.  Etranacogene dezaparvovec (AMT-061 phase 2b): normal/near normal FIX activity and bleed cessation in hemophilia B. , 2019, Blood advances.

[35]  M. Westerman,et al.  Patient Perspectives on Novel Treatments in Haemophilia: A Qualitative Study , 2019, The Patient - Patient-Centered Outcomes Research.

[36]  Hannah A. Blair Emicizumab: A Review in Haemophilia A , 2019, Drugs.

[37]  C. Kempton,et al.  Emicizumab for hemophilia A without inhibitors , 2019, Expert review of hematology.

[38]  M. Makris,et al.  How to discuss gene therapy for haemophilia? A patient and physician perspective , 2019, Haemophilia : the official journal of the World Federation of Hemophilia.

[39]  J. Oldenburg,et al.  Bleeding and safety outcomes in persons with haemophilia A without inhibitors: Results from a prospective non‐interventional study in a real‐world setting , 2019, Haemophilia : the official journal of the World Federation of Hemophilia.

[40]  G. Pierce,et al.  The 1st WFH Gene Therapy Round Table: Understanding the landscape and challenges of gene therapy for haemophilia around the world , 2019, Haemophilia : the official journal of the World Federation of Hemophilia.

[41]  J. Oldenburg,et al.  Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors , 2018, The New England journal of medicine.

[42]  G F Pierce,et al.  Core outcome set for gene therapy in haemophilia: Results of the coreHEM multistakeholder project , 2018, Haemophilia : the official journal of the World Federation of Hemophilia.

[43]  M. Franchini,et al.  Non-factor replacement therapy for haemophilia: a current update. , 2018, Blood transfusion = Trasfusione del sangue.

[44]  Hildegard Büning,et al.  Small But Increasingly Mighty: Latest Advances in AAV Vector Research, Design, and Evolution. , 2017, Human gene therapy.

[45]  J. Oldenburg,et al.  Emicizumab Prophylaxis in Hemophilia A with Inhibitors , 2017, The New England journal of medicine.

[46]  David Hughes,et al.  The cost of severe haemophilia in Europe: the CHESS study , 2017, Orphanet Journal of Rare Diseases.

[47]  X. Anguela,et al.  Adeno-associated viral vectors for the treatment of hemophilia. , 2016, Human molecular genetics.

[48]  V. Arruda,et al.  Obstacles and future of gene therapy for hemophilia , 2015, Expert opinion on orphan drugs.

[49]  E. Panitsides,et al.  Continuing medical education revisited: theoretical assumptions and practical implications: a qualitative study , 2014, BMC medical education.

[50]  Christine Detrembleur,et al.  Three-Dimensional Gait Analysis Can Shed New Light on Walking in Patients with Haemophilia , 2013, TheScientificWorldJournal.

[51]  T. Weber,et al.  Pre-existing anti-adeno-associated virus antibodies as a challenge in AAV gene therapy. , 2013, Human gene therapy methods.

[52]  J. Mahlangu,et al.  Guidelines for the management of hemophilia , 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

[53]  C. Hay,et al.  The principal results of the International Immune Tolerance Study: a randomized dose comparison. , 2012, Blood.

[54]  H. Saito,et al.  Historical perspective and future direction of coagulation research , 2011, Journal of thrombosis and haemostasis : JTH.

[55]  S. Pipe Functional roles of the factor VIII B domain , 2009, Haemophilia : the official journal of the World Federation of Hemophilia.

[56]  J. Astermark,et al.  European principles of haemophilia care , 2008, Haemophilia : the official journal of the World Federation of Hemophilia.

[57]  J. Kahn Informed consent in human gene transfer clinical trials. , 2008, Human gene therapy.

[58]  W. Xiao,et al.  It's all about the clothing: capsid domination in the adeno‐associated viral vector world , 2007, Journal of thrombosis and haemostasis : JTH.

[59]  R. Safeer,et al.  Health literacy: the gap between physicians and patients. , 2005, American family physician.

[60]  K. High AAV‐Mediated Gene Transfer for Hemophilia , 2001, Annals of the New York Academy of Sciences.

[61]  H. Messmore,et al.  Hemostasis and Thrombosis: Basic Principles and Clinical Practice , 2001 .

[62]  G. Watts,et al.  Journals , 1881, The Lancet.

[63]  Winkler,et al.  Evolution of , 2017 .

[64]  R. Colman,et al.  Hemostasis and Thrombosis: Basic Principles and Clinical Practice , 1988 .